CPIX - Cumberland Pharmaceuticals Inc.
| Previous Close | 5.76 |
| Open | 5.66 |
| Bid | 5.64 x 800 |
| Ask | 5.70 x 1000 |
| Day's Range | 5.63 - 5.78 |
| 52 Week Range | 4.83 - 7.00 |
| Volume | 5,635 |
| Avg. Volume | 18,988 |
| Market Cap | 88.398M |
| Beta (3Y Monthly) | -0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.31 |
| Earnings Date | Aug 12, 2019 - Aug 16, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.25 |
- Simply Wall St.•5 days ago
When Will Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Turn A Profit?
Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX): Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company...
- Zacks•12 days ago
Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher
Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.
- Zacks•21 days ago
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
- Zacks•22 days ago
Cumberland Pharmaceuticals (CPIX) Gains As Market Dips: What You Should Know
In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $6.35, marking a +0.79% move from the previous day.
- Zacks•22 days ago
Why Taro Pharmaceutical (TARO) Could Be Positioned for a Slump
Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- Zacks•28 days ago
Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know
Cumberland Pharmaceuticals (CPIX) closed the most recent trading day at $6.19, moving -0.16% from the previous trading session.
- American City Business Journals•28 days ago
The city's newest public company wants to build a new industry in Nashville
“If we can bring the right people and the right brains and build out the infrastructure, we think we can build the industry,” Harrow Health CEO Mark Baum said.
- American City Business Journals•29 days ago
Publicly traded San Diego firm moving HQ to Nashville
A publicly traded health care company is relocating from the West Coast to Nashville — but it won’t be the typical Middle Tennessee health care firm.
- Zacks•last month
The Zacks Analyst Blog Highlights: Flexible Solutions International, Qiwi, Cumberland Pharmaceuticals, CECO Environmental and Entravision Communications
The Zacks Analyst Blog Highlights: Flexible Solutions International, Qiwi, Cumberland Pharmaceuticals, CECO Environmental and Entravision Communications
- Zacks•last month
Has Cumberland Pharmaceuticals (CPIX) Outpaced Other Medical Stocks This Year?
Is (CPIX) Outperforming Other Medical Stocks This Year?
- Zacks•last month
Nektar (NKTR) in Focus: Stock Moves 8.8% Higher
Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CPIX earnings conference call or presentation 14-May-19 8:30pm GMT
Q1 2019 Cumberland Pharmaceuticals Inc Earnings Call
- Zacks•last month
5 Stocks That Survived May's Market Mayhem
A few stocks had what it takes to survive the chaos unleashed by the U.S.-China trade war.
- Zacks•2 months ago
Cumberland (CPIX) Upgraded to Strong Buy: Here's What You Should Know
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Zacks•2 months ago
Is Cumberland (CPIX) a Solid Growth Stock? 3 Reasons to Think " Yes "
Cumberland (CPIX) possesses solid growth attributes, which could help it handily outperform the market.
- PR Newswire•2 months ago
Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement For Distribution In China
NASHVILLE, Tenn., May 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced it has entered into an exclusive agreement with China's Winhealth Pharma Group for the licensing rights of Acetadote® (acetylcysteine) Injection, used to prevent or reduce liver damage resulting from acetaminophen overdose, and Caldolor® (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. The agreement will provide Winhealth licensing rights to commercialize both FDA approved drugs in China, the second largest market for pharmaceuticals in the world after the U.S. There have been patents issued for both brands in China.
- Zacks•2 months ago
Cumberland Pharmaceuticals (CPIX) Q1 Earnings and Revenues Beat Estimates
Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 11.24%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Cumberland: 1Q Earnings Snapshot
On a per-share basis, the Nashville, Tennessee-based company said it had a loss of less than 1 cent. Earnings, adjusted for one-time gains and costs, were 11 cents per share. The pharmaceutical company ...
- American City Business Journals•2 months ago
Nashville health care company's strategic review leads it to China
Cumberland Pharmaceuticals Inc. has entered into an agreement with a Chinese pharmaceuticals firm that will introduce two of the Nashville-based company’s brands to the world’s second-largest market for prescription medicine. The exclusive deal gives Winhealth Pharma Group the licensing rights to sell Cumberland’s drug brands Acetadote and Caldolor in China. CEO A.J. Kazimi said the agreement is expected to generate $290 million in revenue for Cumberland during its first 10 years. The deal is the result of a company-initiated strategic review of Cumberland’s brands and partnerships, which was announced in March.
- PR Newswire•2 months ago
Cumberland Pharmaceuticals Reports 38% Revenue Growth In The First Quarter
NASHVILLE, Tenn. , May 14, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive ...
- Zacks•2 months ago
Analysts Estimate Cumberland Pharmaceuticals (CPIX) to Report a Decline in Earnings: What to Look Out for
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•2 months ago
Cumberland Pharmaceuticals To Announce First Quarter 2019 Financial Results
NASHVILLE, Tenn. , May 7, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2019 financial results after the market closes on Tuesday, ...
- Zacks•2 months ago
What's in Cards for Cumberland (CPIX) This Earnings Season?
Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.
